SOP Guide for Pharma

Elixir Department: SOP for Deviation Management – V 2.0

Elixir Department: SOP for Deviation Management – V 2.0

Standard Operating Procedure for Deviation Management in Elixir Manufacturing

Department Elixir Department
SOP No. SOP/ELX/243/2025
Supersedes SOP/ELX/243/2022
Page No. Page 1 of 8
Issue Date 11/04/2025
Effective Date 15/04/2025
Review Date 11/04/2026

1. Purpose

To define the process for identification, documentation, investigation, evaluation, and closure of deviations occurring during the manufacturing, testing, storage, or handling of elixir products in compliance with cGMP.

2. Scope

This SOP is applicable to all planned and unplanned deviations observed in the Elixir Department across production, quality control, warehouse, and engineering operations.

3. Responsibilities

  • All Department Personnel:
    • Report any deviation observed during routine operations.
  • Department Head:
    • Ensure timely documentation and preliminary impact assessment.
  • QA Officer:
    • Initiate deviation number, coordinate investigation, and ensure timely closure.

4. Accountability

The QA Head is accountable for ensuring compliance with this SOP and regulatory expectations related to deviation investigation and control.

5. Procedure

5.1 Types of Deviations

  • Planned Deviation: A deviation pre-approved by QA for a temporary and controlled change.
  • Unplanned Deviation: Any unexpected incident or non-compliance with approved procedures or
parameters.

5.2 Identification and Documentation

  1. Any deviation observed must be reported immediately to the department supervisor and QA.
  2. QA shall issue a unique deviation number and deviation form (Annexure-1).
  3. The concerned department must fill in:
    • Date and time of deviation
    • Brief description
    • Batch/product details (if applicable)
    • Initial impact assessment

5.3 Investigation and Impact Analysis

  1. QA along with department head shall initiate an investigation.
  2. Determine root cause using tools like:
    • Fishbone diagram
    • 5 Whys technique
  3. Assess potential impact on:
    • Product quality
    • Patient safety
    • Regulatory compliance

5.4 Corrective and Preventive Action (CAPA)

  1. Propose suitable CAPA based on root cause analysis.
  2. Assign responsible persons and timelines for CAPA execution.
  3. QA shall verify CAPA implementation and effectiveness.

5.5 Deviation Closure

  1. Once investigation and CAPA are complete, QA shall:
    • Review deviation file
    • Approve closure with remarks
  2. Deviation shall be closed within 30 working days from initiation unless extended with justification.

5.6 Trending and Review

  1. QA shall maintain a Deviation Register (Annexure-2) and trend deviations monthly.
  2. Include deviation trends in Product Quality Review (PQR).

6. Abbreviations

  • SOP: Standard Operating Procedure
  • QA: Quality Assurance
  • CAPA: Corrective and Preventive Action
  • cGMP: Current Good Manufacturing Practices

7. Documents

  1. Deviation Report Form (Annexure-1)
  2. Deviation Register (Annexure-2)
  3. Root Cause Analysis Record

8. References

  • 21 CFR Part 211.100 – Written Procedures; Deviations
  • ICH Q10 – Pharmaceutical Quality System
  • WHO TRS 986 Annex 2 – GMP for Pharmaceutical Products

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: Deviation Report Form

Deviation No. Date Department Description Batch No. (if any) Initial Impact Raised By
DEV-ELX-025 11/04/2025 Production Mixing time exceeded by 10 minutes ELX-0425-058 Potential impact on homogeneity Rajesh Kumar

Annexure-2: Deviation Register

Deviation No. Date Department Status CAPA Implemented Closed By
DEV-ELX-025 11/04/2025 Production Closed Yes Sunita Reddy

Revision History:

Revision Date Revision No. Revision Details Reason for Revision Approved By
01/01/2024 1.0 Initial SOP Release New SOP Creation QA Head
11/04/2025 2.0 Integrated CAPA timeline and root cause tools Compliance Enhancement QA Head
Exit mobile version